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INTRODUCTION
Mathematical modeling in biology has a long and illustrious history, of providing physical explanations of biological phenomenon--think of Hodgkin & Huxley's model of neuronal action potential propagation (1) . A major tenet of systems biology is to interpret and inform experimental work through an iterative process of mathematical modeling and experimental validation. When considering the structure of signaling pathways, experimental evidence reveals functional or physical interactions that give rise to hypotheses suggesting how a signal is transduced through the pathway. However, experiments done under different experimental conditions typically suggest several plausible pathway topologies, and it becomes difficult to distinguish which connections cells actually use as the number of potential connections grows. The comprehensive map of the epidermal growth factor (EGF) signaling network illustrates this problem, because when all possible connections are described (2) , it is impossible to tell which ones are realized in a particular situation. It was demonstrated by Wilkinson (3) that, in principle, competing mathematical models of biochemical pathways can be evidentially ranked in an objective manner using experimental data. Thus, we suggest and employ a Bayesian Inference-Based modeling (BIBm) approach, founded on Wilkinson's assumption, that provides the means to rank alternative hypotheses about pathway structures on the basis of the evidence provided by experimental data.
BIBm takes a number of working hypotheses about the structure and dynamics of a biological process, which have attached to them preliminary levels of confidence in their validity. These levels of confidence, or prior probabilities, are informed by existing knowledge and can be formally represented as a calibrated probability distribution over all hypotheses under consideration (4) . An abstracted mathematical model explicitly capturing all assumptions and describing the main phenomena of the system then formally represents each hypothesis (5) . Unlike other computational systems biology modeling approaches in which a single model is considered and subsequently refined, BIBm considers all of the plausible enumerated hypotheses in the form of mathematical models based on the amount and quality of evidential support for each of the instantiated models. This formalizes the 'exploration of hypothesis space' in that different plausible alternatives are evaluated in terms of confidence based on the strength of evidential support for each one (5) . Thus, the Bayesian probabilistic framework (3-5) provides a rigorous formal methodology for characterizing and propagating uncertainty based on experimental data during model evaluation and provides the means to update the levels of confidence in each hypothesis in light of the information content of experimental data (see Supplementary Material, sections 1 and 4).
Furthermore, the Bayesian hypotheses testing methodology used in the BIBm framework accounts for model complexity (6) . We do not take a single optimal point of the likelihood, i.e. a single plausible value, but rather integrate (marginalize) over all of the model parameters taking into account their likely distribution as measured or estimated based on prior knowledge (prior distribution) and the likelihood. Thus, overly complex models are automatically penalized, and BIBm assigns the highest ranking to the simplest model(s) that suffice to explain the experimental evidence. The updated probabilities (posteriors) may re-rank and select between prior hypotheses, or suggest further experimentation, if preconceived models have similar weights of posterior probability (5, 6) . This procedure is iterated until the obtained inferences allow to draw conclusions in respect to the original hypothesis about the biological system closing the cycle of hypothesis generation, model development, model assessment, and experimental validation (Fig. 1) . Thus, BIBm permits evaluation of pathway models based on a limited set of measurements and multiple perturbations, and it accommodates dynamic models within a probabilistic framework.
We tested BIBm on the real biological network of the activation of the extracellular signal-regulated kinase (ERK) pathway by EGF, with ERK activation as the readout. We perturbed the pathway by pharmacologically inhibiting or activating adenosine 3',5'-monophosphate (cAMP) signaling, which has several points of crosstalk with the EGF-mediated activation of ERK (7, 8) . The ERK pathway is activated by surface receptors, such as the EGF receptor (EGFR), which activate a Ras family guanosine triphosphatase (GTPase) at the cell membrane by recruiting guanine nucleotide exchange factors (GEFs) that exchange GDP for GTP (9) . Ras-GTP binds to and initiates the activation of kinases of the Raf family. Raf then phosphorylates and activates mitogen-activated protein kinase kinase (MEK), and MEK phosphorylates and activates ERK (9) (10) (11) . ERK participates in the regulation of fundamental cellular processes (12) , and its deregulation is implicated in the pathogenesis of many diseases, especially cancer (10). Deregulation typically occurs at the level of Ras and Raf activation, a complex part of the pathway with many possible isoforms and regulatory inputs. Ras activates all three Raf isoforms A-Raf, B-Raf, and Raf-1, whereas B-Raf can also be activated by another GTPase Rap1 (8, 13) . However, activation of EPAC, a Rap1 GEF, by the cAMP analog 8CPT-2Me-cAMP did not activate ERK (14) , and it is unclear which growth factors and under what conditions Rap1 activates B-Raf (15) . cAMP signaling can inhibit Raf-1 and activate B-Raf (7) confounding the analysis of cAMP effects on ERK activity in cells where both Raf-1 and B-Raf are present. Exploring all possibilities experimentally would require a prohibitively large number of experiments. Thus, we used BIBm to analyze the most plausible pathway topologies based on a limited, and hence feasible, set of experimental measurements.
RESULTS

Application of BIBm to analyze the EGF activated ERK pathway
On the basis of the published literature, we selected four different equally plausible pathway topologies for EGF-mediated activation of ERK ( Fig. 2A ). Model details are described in section 3 of the Supplementary Materials. In Model 1, activation of ERK proceeds through Ras (16, 17) and the model includes the possibility that Ras activates both Raf-1 and B-Raf (18). In Model 2, two branches of ERK activation occur through Ras and Rap1 (8, 13) . Models 3 and 4 correspond to Models 1 and 2, but include EGFR desensitization, which may critically regulate ERK activity (19) .
By assessing the informativeness of measurements of different species in the pathway, we found that ERK activity provided the most informative data with an eigenvalue of 0.2127, which was 0.57 times greater than the next best data set (MEK, with an eigenvalue of 0.1216) (see Materials and Methods and Supplementary Materials, section 1). Therefore, we measured the kinetics of ERK activation in PC12 cells under 11 distinct conditions and perturbations, which represented a total of 168 experimental measurements (Supplementary Materials, section 2.3). Each time point and each replicate is considered a separate measurement. To perturb the pathway, we used drugs affecting the activity of the cAMP signaling system, which has multiple points of crosstalk with the EGF-stimulated ERK activation pathway ( Fig. 2A and Fig. S1 ). We targeted protein kinase activated by cAMP (PKA) with the cAMP analog 6-Benz-cAMP, EPAC with the cAMP analog 8pMeOPT-2-O-cAMP, and phosphodiesterase 3 (PDE3) with cilostamide, which we determined was the most active PDE in PC12 cells (Fig. S2D ). We simulated model dynamics with Bayes' factor is a summary of the evidence provided by the data in favor of one scientific hypothesis, represented by a mathematical model, in comparison to another. Posterior odds for preferring one model to another can be obtained by multiplying the Bayes' factor by the prior odds. Thus, we can base our ranking on probability distributions, which give us exact information on the probability that our conclusions are correct.. Comparing 
3B-D).
We also knocked down Raf-1 and B-Raf, which are the relevant Ras Using confocal microscopy and biochemical cell fractionation, we examined whether knocking down GRB2 or CRK, or both, would alter the subcellular localization and EGF mediated membrane recruitment of Raf-1 and B-Raf, but no significant changes were observed ( 
DISCUSSION
The results that the EGFR uses at least two different complexes of adaptor proteins and GEFs and two different Raf isoforms to activate ERK was unexpected. The prevalent opinion in the field is that B-Raf is the major activator of the ERK pathway, although data from Raf isoform knockout mice have shown that either Raf-1 or B-Raf may function, depending on cell type and context (30) . Our method provides a rational and tractable framework for capturing such complex relationships. For instance, the cAMP crosstalk with the EGF-activated ERK pathway is highly specific. In PC12 cells, PKA activation slightly inhibits ERK activation, whereas EPAC activation, or even more efficiently, PDE3 inhibition increases ERK activation by EGF (Fig. 2B ).
Although PKA is distributed throughout the cell, PDE3 resides at the membrane and hence has a localized effect on cAMP abundance (31) . Thus, increases in cAMP can have entirely different effects, depending on how and where it is generated (32, 33) . This intricate functional differentiation could be implicitly captured by BIBm analysis. compatible with high-throughput assay platforms, which typically measure a single output under multiple perturbation conditions. Thus, MRA and BIBm seem highly complementary, and it will be interesting to explore whether they can be combined for enhanced pathway mapping.
MATERIALS AND METHODS
Implementation of BIBm
The statistical and technical challenges in computing the probabilities of the dynamical system models are formidable, especially when only sparse data sets are available (3, 5, 7) . BIBm overcomes this problem with a combinatorial strategy that is briefly described here and fully described in the 
where the expectation is taken with respect to the power-posterior the sampling density of the n'th stratum:
Setting each of the sampling densities of the strata to be uniform,
Samples  m n~p ( D,S i ,˜  n ) were obtained using MCMC based on the Metropolis-Hastings scheme.
Mathematical models and Bayesian inference
Detailed mathematical descriptions of the four ODE models are presented in the Supplementary Materials, section 3. Most of the reactions are described by the Michaelis-Menten kinetic law either directly or in a modified form where the enzyme concentration is taken into account similar to the modeling approach employed by Brown et al. (16) . There are about 20 species and 50 parameters involved in the considered models. We formulate our prior distributions of model parameters on the presumption that all the biochemical processes are slow enough to be observed. Thus, the value for the limiting rate should be small, and the value for the Michaelis constant should be on the same scale as our initial concentrations. Because rate parameters are strictly positive, we employ the Gamma distribution for the limiting rate of the reaction(1.1,9.0), where (a,b) denotes a Gamma distribution (37) We performed Bayesian model comparison to assess the proposed hypotheses about the pathway structure embodied in models 1, 2, 3 and 4.
We describe a Stratified Path Sampling strategy with Population MCMC, which was used to obtain estimates of the required marginal likelihoods (see Supplementary Materials. Section 4.1 for details).
Perturbation analysis in PC12 cells
The experimental data were measured as relative concentrations of double 
Antibodies, cells, and siRNAs for biochemical validation experiments
Monoclonal antibodies for GRB2, CRK, and Raf-1 were from BD. For rat PC12 cells, smart-pool siRNAs (Dharmacon) were used to knockdown Raf-1 and B-RAF, and a nonTargeting siRNA pool (Dharmacon) was used as control. 40 pM siRNA oligonucleotides were introduced into PC12 cells by nucleofection (Amaxa Biosystems, Germany) according to the manufacturer's instructions. Cells were seeded on collagen, 24h later serum starved overnight, and then stimulated with 20 ng/ml EGF.
ERK1/2 phosphorylation assay in validation experiments
Hek 293 cells transfected with siRNA were rendered quiescent by serum starvation for 6 or 12 hours prior to stimulation with 10 ng/ml EGF for 0, 2, 5, 
Raf-1 -B-Raf coimmunoprecipitation experiments
Cells were lysed in immunoprecipitation buffer (150 mM NaCl, 0.01 mM NaPO4, 2 mM EDTA, 1mM Na 3 VO 4 , 0.5% Triton X-100 and 5% glycerol plus Figure S1 . Effect of cAMP modulation on EGF stimulated ERK activation. Figure S2 . The structure of a crosstalk between cAMP and ERK pathways. Figure S3 . Activation of endogenous Rap1 does not prevent Raf-1 activation and does not mediate cAMP-induced inhibition of Raf-1 Figure S4 . Raf-1 and B-Raf localization. 
